title: Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation.
abstract: We have cloned a human Hevin cDNA from omental adipose tissue of different patients by reverse transcription polymerase chain reaction and shown a sequence variation due to a possible polymorphism at amino acid position 161 (E/G). Hevin protein expressed in vitro showed molecular weights of approximately 75 kDa and 150 kDa, suggesting that Hevin may form a homodimer in vitro. Using Northern blots and a human expressed sequence tAg database analysis, Hevin was shown to be widely expressed in human normal or non-neoplastic diseased tissues with various levels. In contrast to this, its expression was strongly down-regulated in most neoplastic cells or tissues tested. However, neither the mechanism nor the physiological meaning of this down-regulation is known. As an initial step towards investigating the functional role of Hevin in cell growth and differentiation, we transiently or stably expressed this gene in cancer cells (HeLa 3S) that are devoid of endogenous Hevin and measured DNA synthesis (cell proliferation) by 5-bromo-2'-deoxyuridine incorporation. Hevin was shown to be a negative regulator of cell proliferation. Furthermore, we have shown that Hevin can inhibit progression of cells from G1 to S phase or prolong G1 phase. This is the first report which describes the function of Hevin in cell growth and proliferation. Through database analysis, Hevin was found to be located on chromosome 4 which contains loss of heterozygosity of many tumour suppressor genes. Taken together, these results suggest that Hevin may be a candidate for a tumour suppressor gene and a potential target for cancer diagnosis/therapy.
authors.affiliation: Department of Biochemistry, Janssen Research Foundation, Beerse, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Claeskens
authors.forename: N
authors.initials: N
authors.lastname: Ongenae
authors.forename: J M
authors.initials: JM
authors.lastname: Neefs
authors.forename: P
authors.initials: P
authors.lastname: Cheyns
authors.forename: P
authors.initials: P
authors.lastname: Kaijen
authors.forename: M
authors.initials: M
authors.lastname: Cools
authors.forename: E
authors.initials: E
authors.lastname: Kutoh
mesh_terms: D015152:Blotting, Northern; D002135:Calcium-Binding Proteins / Q000096:biosynthesis* / Q000494:pharmacology; D002453:Cell Cycle / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D002471:Cell Transformation, Neoplastic; D004273:DNA, Neoplasm / Q000235:genetics; D015536:Down-Regulation; D016326:Extracellular Matrix Proteins; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D006023:Glycoproteins / Q000096:biosynthesis* / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D014407:Tumor Cells, Cultured
chemical_list: D002135:Calcium-Binding Proteins; D004273:DNA, Neoplasm; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; C503126:SPARCL1 protein, human